BioVie, an early stage biotech developing therapies for cirrhosis, announced terms for its IPO on Tuesday.
The Los Angeles, CA-based company plans to offer 1.3 million shares and raise $15 million based on an offer price of $11.88, the as-converted last close of its shares listed on the OTC (BIVI). At this price, BioVie would command a fully diluted market value of $64 million.
BioVie was founded in 2013 and plans to list on the Nasdaq under the symbol BIVI. ThinkEquity is the sole bookrunner on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.